Ann: Regeneus and AGC collaborate on Progenza in Japan, page-57

This deal is certainly a company maker for RGS, and with that upfront payment, and other payments coming as part of the deal, there should be no concerns of a cash raise.

Validation in the Japanese market will open up doors into other large markets in the next year or so IMO. As has been said, deals like this dont come by every day.

Had been eyeing this stock for a while, it's a good little stem cell play with a small register, it's very derisked now, and likely to have a booming 2017, so glad to be on board.